NeueHealth, Inc. (NYSE:NEUE) corporate secretary Jeffery Michael Craig has recently sold company stock, primarily to satisfy tax withholding obligations related to the vesting of restricted stock units. The transactions, which were not discretionary, involved the sale of a total of 256 shares of common stock, resulting in proceeds exceeding $1,800.
The sales took place over two days, with 105 shares sold on March 14 and an additional 151 shares on March 15. The weighted average prices per share for these transactions were $7.06 and $7.10, respectively. However, the actual sales occurred at varying prices within a range; on the first day, shares were sold at prices between $6.76 and $7.45, and on the second day, between $6.98 and $7.40.
Following these transactions, Craig's ownership in the company's common stock has decreased, yet he still retains 3,686 shares. The sales were executed in a non-discretionary manner, as they were directly associated with the vesting schedule of Craig's restricted stock units, a common practice among corporate executives to manage tax liabilities.
Investors and followers of NeueHealth's stock movements can observe these recent sales as part of the routine financial management activities of the company's executives. The details provided in the footnotes of the SEC Form 4 filing underscore the non-discretionary nature of the sales, emphasizing that they were conducted to meet tax obligations rather than based on Craig's market outlook or investment strategy.
For further information and full details regarding the number of shares sold at each separate price within the specified range, the reporting person has committed to providing the necessary data to the issuer, security holders, or the SEC upon request.
InvestingPro Insights
NeueHealth, Inc. (NYSE:NEUE) has been navigating a challenging market environment, with recent executive stock sales highlighting the company's ongoing financial activities. In the context of the market's reception to these developments, InvestingPro provides deeper insights into the company's financial health and stock performance.
According to InvestingPro, NeueHealth is experiencing a period of significant financial pressure. The company's quick cash burn and analysts' expectations of a sales decline this year suggest that investors should be cautious. This is further substantiated by the company's short-term obligations exceeding its liquid assets, indicating potential liquidity concerns. Moreover, the absence of dividends may limit the stock's appeal to income-focused investors.
Looking at the real-time data, NeueHealth's market cap stands at a modest 57.6 million USD, reflecting the small size of the company within its industry. The company's recent revenue figures have shown a substantial decline, with a -51.87% change in the last twelve months as of Q4 2023. This revenue contraction is a critical factor for investors to consider, especially in light of the company's gross profit margin of 14.15% during the same period. Although the company has seen a strong return of 32.25% over the last three months, the broader picture shows a significant price drop of -66.83% over the past year, suggesting a high level of volatility and potential risk for shareholders.
Investors seeking a more comprehensive analysis of NeueHealth can find additional InvestingPro Tips on the platform. For instance, the company's valuation implies a poor free cash flow yield, and analysts do not anticipate profitability this year. With a total of 10 InvestingPro Tips available, users can gain an in-depth understanding of the company's financial nuances and stock performance. For those interested in accessing these insights, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
While the recent stock sales by corporate secretary Jeffery Michael Craig were for tax purposes and not a reflection of the company's market outlook, the broader financial data provided by InvestingPro indicates that NeueHealth faces considerable challenges ahead. Investors would do well to monitor these metrics closely when making investment decisions regarding NEUE stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.